Bio-Path reports interim Phase II data for AML candidate

Bio-Path Holdings Inc. (NASDAQ:BPTH) reported interim data from 17 evaluable patients with previously untreated acute myelogenous leukemia (AML) who are ineligible for intensive induction therapy in a Phase II trial showing that prexigebersen (BP1001) plus low-dose cytarabine led to four complete remissions and four cases of stable disease. The company said the open-label, U.S. trial will be expanded to a total of 54 patients.

The trial's primary endpoint is complete remission rate. Secondary endpoints include overall survival (OS), time to response, duration of response, safety and pharmacokinetics...